The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I StudyMatthew S. Davids, John F. Seymour, Lori A. Gressick et al.|Blood|2012Cited by 40
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).John F. Seymour, Andrew W. Roberts, Matthew S. Davids et al.|Journal of Clinical Oncology|2013Cited by 33
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al.|Journal of Clinical Oncology|2013Cited by 12
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human StudyJohn F. Seymour, Andrew W. Roberts, Matthew S. Davids et al.|Blood|2012Cited by 10